Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 19 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

 		Prostatic Neoplasms, Castration-Resistant Phase 1 Australia
South Africa

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

 		MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Phase 1 Japan
Korea, Republic of
Singapore

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

 		Prostate Cancer Phase 4 United States

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

 		Breast Cancer France

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

 		Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 2 China

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

 		Advanced Breast Cancer Phase 4 India

A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers

 		Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck Phase 1 United States
Hong Kong
Singapore
Taiwan
Canada
View All

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

 		Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation Phase 2 Malaysia
Turkey
Thailand
Spain
Italy
China
Brazil
Germany
Bulgaria
Netherlands
France
Argentina
Austria
Portugal
Hungary
Belgium
United Kingdom
View All

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

 		Non-small Cell Lung Cancer Phase 1 United States
Spain
Japan
Germany
Korea, Republic of
View All

A Safety Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients in Combination With Carboplatin, Etoposide and Tislelizumab

 		Extensive Stage Small Cell Lung Cancer Phase 1 United States
Spain
Germany
France
View All